The Hong Kong and Macao Medicine and Equipment Connect policy was implemented in Zhongshan's Chenxinghai Hospital on February 18. Patients now can use the new imported oral anticancer drugs "Lorlatinib" and "Entrectinib" through this policy, just like citizens in Hong Kong and Macao, without leaving Zhongshan.

Because "Lorlatinib" and "Entrectinib" are not yet available on the market in mainland China, patients would need to go to Hong Kong or Macao to buy these two drugs. Now they have been permitted for use in Chenxinghai Hospital, which is convenient for patients.

"The new drugs not only bring hope to patients who failed to get further treatment, but also promote the deep integration of drugs and medical devices between Guangdong and Hong Kong and Macao," said Su Shengfeng, a member of the Guangdong Provincial Medical Products Administration (GDMPA) Party Group.